Yposkesi. (2/28/22). "Press Release: Yposkesi, an SK pharmteco Company, Appoints US-based Executive Director for Business Development". Corbeil-Essonnes.

	Region	United States (USA)
	Organisation	Yposkesi (FR)
	Group	SK Group (Group)
	Organisation 2	Patheon Inc.
	Group	Thermo Fisher (Group)
	Product	viral vector production technology
	Product 2	lentiviral vector
	Person	Hultén, Corrie (SK Group 202202– Executive Director Business Development before Porton Advanced + Patheon)
	Person 2	Lamproye, Alain (Yoskesi 201807 CEO before Novasep 201511 President of Biopharma Business Unit)

With close to 20 years’ biotech and pharma industry experience, Corrie Hulten will spearhead growth opportunities for Yposkesi, as its capacity to manufacture cell and gene therapies for clients expands globally

Yposkesi, SK pharmteco’s clinical and commercial viral vector manufacturing arm for cell and gene therapies, today announces the appointment of Corrie Hulten as executive director, business development.

In her new role, Ms. Hulten will strengthen Yposkesi’s presence in the greater Boston (MA) area, home to more than 1,000 biotechs, and attract new business opportunities for its full-service offering in lentiviral vectors & AAV (Adeno-Associated Virus) manufacturing across the East coast and beyond in the US.

“We are really excited to welcome Corrie to Yposkesi. Her wealth of expertise and networking within the US biotech and pharma industry, as well as market insights, make her a tremendous addition to the team,” said Alain Lamproye, executive chairman of Yposkesi. “I firmly believe that her skills and dynamism will contribute significantly to our commercial development and to the wider success of our company.”

Ms. Hulten joins Yposkesi as the company nears completion of its second state-of-the-art commercial production facility, a new global resource for drug developers of cell and gene therapies (C>). C>, a fast-growing field, are a promising class of medicines that offer the possibility of curing conditions with a genetic basis that have few or no other therapeutic options for patients.

The construction of Yposkesi’s second 5,000m2 (50,000 ft²) building site, designed for European and American GMP compliance, will be completed by July 2022 and operational by mid-2023. It will address the shortage in manufacturing capacity for drug developers seeking to advance clinical trials and commercialize new therapeutic drugs.

“I’m very excited to join Yposkesi and be a part of its strong team, who have deep cell and gene therapy manufacturing expertise and experience far beyond many players in the market,” said Ms. Hulten. “As its operational capacities expand, Yposkesi is poised to make a significant difference in delivering to drug developers the quality and volume of Advanced Therapy Medicinal Products (ATMP) required to treat patients with rare and life-threatening diseases.”

Ms. Hulten has served as director, business development with Porton Advanced and as a business development executive with Patheon. Prior to that, she worked for an international corporation in fine chemicals for five years, following two years in procurement with a B2C product developer and more than seven years in chemistry R&D sourcing and project management. Ms. Hulten studied biotechnology at Harvard University.

About Yposkesi

Yposkesi, an SK pharmteco company, is one of the largest Contract Development and Manufacturing Organization’s (CDMO) in Europe. Dedicated to viral vector manufacturing for gene therapy, Yposkesi is a one-stop shop offering a full range of services for lentiviral vectors & AAV (Adeno-Associated Virus) manufacturing: feasibility study, bioprocess development (upstream/downstream & fill and finish), analytical development, small/pilot to large-scale production, cGMP manufacturing of clinical batches, quality control & assurance and regulatory support. With a current 50,000ft2 (approx. 5,000m2) footprint, Yposkesi’s facility operates multiple manufacturing suites for bulk drug substances (up to 1,000L) and Fill & Finish. By 2023, the company will increase its global footprint to 100.000ft2 (approx. 10,000m2) with a second large-scale facility designed for EMA and FDA compliance. Yposkesi sustainably invests in bioprocessing innovation in order to deliver high quality gene-modified cell therapies and in vivo gene therapy projects. Yposkesi employs around 200 people and is located on the Genopole Campus in Corbeil-Essonnes (South of Paris), France.

www.yposkesi.com

Media and analyst contact

Andrew Lloyd & Associates
Carol Leslie / Juliette Schmitt
carol@ala.com / juliette@ala.com
UK and US: +44 1273 675 100
@ALA_Group

Record changed: 2023-06-05